[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100544452":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":35,"locations":41,"responsibleParty":65,"collaborators":25,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":69,"sex":75,"minAge":76,"maxAge":25,"enrollmentInfo":77,"targetDuration":25,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":88,"overallStatus":44,"whyStopped":25,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"Centre Hospitalier Universitaire de Nīmes","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"CVVHD","EXPERIMENTAL","Patient requiring renal remplacement therapy treated with by continuous venovenous hemodialysis (CVVHD) method.",[13],"Other: CVVHD Dialysis parameters",{"label":15,"type":16,"description":17,"interventionNames":18},"CVVHDF","ACTIVE_COMPARATOR","Patient requiring renal remplacement therapy treated with by continuous venovenous hemodiafiltration (CVVHDF) method.",[19],"Other: CVVHDF Dialysis parameters",[21,26],{"type":6,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"CVVHD Dialysis parameters","Patients will receive a CVVHD dialysis with a dose of 25ml\u002Fkg\u002Fh dialysate (100% dialysate), with Fresenius Medical Care multiFiltrate PRO kit and Ultraflux AV1000S filter (polysuflone 1.8m²).Regional anticoagulation with citrate",[9],null,{"type":6,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"CVVHDF Dialysis parameters","Patients will receive a CVVHDF dialysis with a dose of 25ml\u002Fkg\u002Fh dialysate (50% ultrafiltration, 50% dialysate), with Fresenius Medical Care multiFiltrate PRO kit and Ultraflux AV1000S filter (polysuflone 1.8m²). Systemic anticoagulation with heparine",[15],[31],{"name":32,"affiliation":33,"role":34},"Claire Roger","CHU Nimes","PRINCIPAL_INVESTIGATOR",[36],{"name":37,"role":38,"phone":39,"phoneExt":25,"email":40},"Claire Roger, MD","CONTACT","04.66.68.30.50","Claire.roger@chu-nimes.fr",[42],{"facility":43,"status":44,"city":45,"state":25,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"CHU de Nimes","RECRUITING","Nîmes","30029","France","FR",{"type":50,"coordinates":51},"Point",[52,53],4.35788,43.83665,{"lat":53,"lon":52},[56,59,60,63],{"name":57,"role":38,"phone":25,"phoneExt":25,"email":58},"Claire Roger, MD, PhD","claire.roger@chu-nimes.fr",{"name":57,"role":34,"phone":25,"phoneExt":25,"email":25},{"name":61,"role":62,"phone":25,"phoneExt":25,"email":25},"Aurèle Buzancais, MD","SUB_INVESTIGATOR",{"name":64,"role":62,"phone":25,"phoneExt":25,"email":25},"Sylvain Garnier, MD",{"type":66,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100544452","continuous-veno-venous-hemodialysis-and-continuous-veno-venous-hemodiafiltration-on-urea-reduction-rate-in-intensive-care-patient-100544452",false,"NCT06369064","Continuous Veno-venous Hemodialysis and Continuous Veno-venous Hemodiafiltration on Urea Reduction Rate in Intensive Care Patient","Comparison of the Effectiveness of Continuous Veno-venous Hemodialysis and Continuous Veno-venous Hemodiafiltration on Urea Reduction Rate in Intensive Care Patients With Acute Renal Injury : a Monocentric Controled Randomized Non Inferiority Open Labeled Study","CompEER","Inclusion criteria:\n\n* Adult patients hospitalized in ICU\n* Undergo RRT session because of AKI stage 3\n* At least one among criteria: pH \\\u003C 7,20 \u002F Blood urea \\> 30mM \u002F Fluid overload uncontrolled by with PaCO₂ \\\u003C 35 mmHg or mixed acidosis with PaCO₂ \\\u003C 50 mmHg.\n\n  * Oliguria lasting 72 hours or longer\n* Patients undergoing their first session of extracorporeal blood purification, initiated less than 12 hours prior to randomization\n* Patient having given free and informed consent, and having signed the consent form or patient included in an emergency situation\n* Patient affiliated with Social Security.\n\nExclusion criteria:\n\n* End-stage chronic kidney disease on dialysis\n* Intoxication with a dialyzable toxin (lithium\n* Criteria for emergency dialysis initiation: hyperkaliemia \\>6,5mM with electrocardiographic signs\n* Medical contraindication to regional citrate: severe liver failure\n* Medical contraindication to anticoagulation or heparin anticoagulation: heparin induced thrombopenia or uncontrolled bleeding\n* Pregnant women, parturient or breast-feeding patient","ALL","18 Years",{"count":78,"type":79},80,"ESTIMATED","INTERVENTIONAL",[82],"NA","In patients requiring renal replacement therapy (RRT) in the intensive care unit (ICU), continuous techniques are predominantly using due to better hemodynamic tolerance. The most employed techniques in ICU are continuous venovenous hemodiafiltration (CVVHDF) and continuous venovenous hemodialysis (CVVHD).\n\nTo our knowledge, there are no prospective studies comparing the efficiency of these two techniques with the same dose of dialysis (and the same filter).\n\nIn the CompEER study, we aim to compare the efficiency of CVVHD and CVVHDF on urea reduction rate in intensive care patients with acute kidney injury.\n\nThe research hypothesis is that CVVHD citrate technique is as effective as CVVHDF heparin technique for urea reduction and provides prolonged and stable clearance, facilitating antibiotic management during RRT.",[85,86,87],"Acute Kidney Injury","Continuous Renal Replacement Therapy","Intensive Care Unit",[89,90,91],"continuous venovenous hemodiafiltration","continuous venovenous hemodialysis","urea reduction rate","2026-05-15",{"date":94,"type":95},"2026-05-18","ACTUAL",{"date":97,"type":95},"2024-07-03",{"date":99,"type":79},"2028-08-15",{"name":5,"class":6},1]